On March 18, 2022 Ichnos Sciences Inc., a global biotechnology company developing innovative biologics in oncology, reported that preclinical data on ISB 1442, a first-in-class bispecific antibody for relapsed/refractory multiple myeloma and other CD38 positive hematologic malignancies, at the Immuno-Oncology 360 (IO360) conference (Press release, Ichnos Sciences, MAR 18, 2022, View Source [SID1234610336]). President and Chief Executive Officer of Ichnos, Cyril Konto, M.D., shared the data in a presentation titled "Beyond the T cell: Co-targeting CD38 and CD47 with a 2+1 Biparatopic Multispecific Antibody" during an afternoon session of the conference.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In addition to presenting data for ISB 1442, Dr. Konto provided a description of Ichnos’ proprietary BEAT platform1 to meeting attendees. More specifically, he shared in vivo and in vitro study results showing the potency and anti-tumor effects of ISB 1442 relative to clinical benchmarks, daratumumab and agrolimab, and highlighted the flexibility of BEAT, which utilizes advanced heavy chain pairing and a common light chain, allows for modulation of the Fc functionality, and enables the exploration of the full design space.
The IO360 Conference is an annual gathering that convenes stakeholders from across the scientific and business communities, providing a forum to share the latest innovations in immuno-oncology. Ichnos was pleased to be a part of the agenda, which also included presentations by institutions such as John’s Hopkins University and several Fortune 100 pharmaceutical companies.
"Events such as IO360 are a great opportunity to learn about the latest in immuno-oncology and to exchange ideas with colleagues across the field," said Dr. Konto. "I am pleased to have had the opportunity to present data on ISB 1442, and Ichnos’ proprietary BEAT platform at the meeting."